following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv).
.
.
.
.
.
but shocking figures uncovered by labour yesterday show some patients are suffering agonising waits of as many as 541 days to begin treatment.
.consider making a donation to support the coverage that shapes the face of berkeley.
.
.
.
.
u.s.